AAA
KPTI icon

Affinity Asset Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Affinity Asset Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-157,600
Closed -$1.03M – 107
2025
Q3 		$1.03M Buy
157,600
+100
+0.1% +$538 0.09% 84
2025
Q2 		$679K Buy
+157,500
New +$773K 0.09% 75

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Affinity Asset Advisors's KPTI Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Karyopharm Therapeutics (KPTI) stake by 38% in Q2 2026, selling an estimated $1.63M and leaving 312,500 shares worth $3.05M. The position accounts for 0.14% of the portfolio, ranked #91.

Affinity Asset Advisors first reported a position in KPTI in Q4 2022 and has held it in 5 quarters since. The position peaked at $6.55M in Q4 2025. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Affinity Asset Advisors held 312,500 shares of Karyopharm Therapeutics worth $3.05M as of Q2 2026.
  • Affinity Asset Advisors sold 187,500 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.63M.
  • Karyopharm Therapeutics made up 0.14% of Affinity Asset Advisors's portfolio in Q2 2026, its #91 holding.
  • Affinity Asset Advisors first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • Affinity Asset Advisors's Karyopharm Therapeutics position peaked at $6.55M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.